Table 4 Baseline and 3-month and 6-month tocilizumab therapy evaluation criteria in eight patients with peripheral spondyloarthritis
Patient 14 | Patient 15 | Patient 16 | Patient 17 | Patient 18 | Patient 19 | Patient 20 | Patient 21 | |
|---|---|---|---|---|---|---|---|---|
DAS28 | ||||||||
M0 | 4.02 | 4.52 | 5 | 4.58 | 5.41 | 6.2 | 5.23 | 4.92 |
M3 (absolute value) | 2.82 | 3.85 | 4.3 | 2.88 | 3.18 | 1.1 | 5.1 | 4.70 |
M3 EULAR response (yes/no) | Yes (good) | No | Yes (moderate) | Yes (good) | Yes (good) | Yes (remission) | No | No |
M6 (absolute value) | 1.95 | 4.01 | 5.34 | 3.12 | NA | NA | NA | NA |
M6 EULAR response (yes/no) | Yes (remission) | No | No | Yes (good) | NA | NA | NA | NA |
ASDAS | ||||||||
M0 | 2.41 | 4.03 | MD | MD | MD | 3.8 | 3 | MD |
M3 (absolute value) | 1.50 | 2.64 | MD | MD | MD | 1.35 | 3.1 | MD |
M6 (absolute value) | 1.03 | 2.79 | MD | MD | MD | NA | NA | MD |
SJCa | ||||||||
M0 | 7 | 2 | 2 | 0 | 3 | 9 | 4 | 7 |
M3 (absolute value) | NA | NA | NA | NA | 7 | 0 | 3 | 6 |
M6 (absolute value) | 0 | 6 | 1 | 0 | NA | NA | NA | NA |
TJCa | ||||||||
M0 | 7 | 6 | 5 | 5 | 0 | 15 | 7 | 12 |
M3 (absolute value) | NA | NA | NA | NA | 0 | 0 | 6 | 11 |
M6 (absolute value) | 2 | 4 | 3 | 8 | NA | NA | NA | NA |
BASDAI, 0 to 100 | ||||||||
M0 | 42 | 75 | NA | 79.4 | 67 | 48 | 4.7 | NA |
M3 (change from M0; %) | -31 | -6.7 | NA | -9 | +6 | NA | -2.1 | NA |
M6 (change from M0; %) | -59.5 | -4.7 | NA | -32 | NA | NA | NA | NA |
BASFI, 0 to 100 | ||||||||
M0 | 40 | 72 | MD | MD | 54 | 70 | NA | NA |
M3 (change from M0, %) | -17.5 | -26 | MD | MD | +44 | NA | NA | NA |
M6 (change from M0, %) | -12.5 | -12.5 | MD | MD | NA | NA | NA | NA |
Pain VAS, 0 to 10 | ||||||||
M0 | 1.5 | 7 | 5 | 7 | 7 | 5 | 6 | 8 |
M3 (absolute value) | 2 | 8 | NA | 6 | 8 | 1 | 6.5 | 6 |
M6 (absolute value) | 1 | 9 | 6 | 7.5 | NA | NA | NA | NA |
PGA, 0 to 10 | ||||||||
M0 | 1 | 6 | 7 | 7.5 | 7 | 5.2 | 6.5 | 8 |
M3 (absolute value) | 3.5 | 6 | MD | MD | 7 | 1 | 6.5 | 8 |
M6 (absolute value) | 1.2 | 6 | 8 | MD | NA | NA | NA | NA |
CRP (mg/dl)a | ||||||||
M0 | 20.2 | 17 | 119 | 12 | 112.3 | 65 | 4 | 1 |
M3 (absolute value) | NA | NA | NA | NA | 9.5 | 1 | 5 | 1 |
M6 (absolute value) | 0.4 | 0.8 | 128 | 1 | NA | NA | NA | NA |
ESR (mm)a | ||||||||
M0 | 39 | 22 | 67 | 26 | 103 | 60 | 27 | 7 |
M3 (absolute value) | NA | NA | NA | NA | 8 | 4 | 7 | 8 |
M6 (absolute value) | 5 | 7 | 70 | 2 | NA | NA | NA | NA |